Table 2.

Percent of Patients with an Increase in Dose After One Year

	Infliximab		Etanercept
	Patients with 3+ infusions	Pct with an increase in dose	Patients with 3+ infusions	Pct with an increase in dose	p-value
Overall	598	57.9%	950	18.1%	<0.001
by Pre-period RA Costs
Quartile 1 – $0 to $502.89	157	49.7%	230	16.5%	<0.001
Quartile 2 – $502.90 to $975	157	62.4%	230	18.7%	<0.001
Quartile 3 – $975.15 to $176	135	57.8%	252	15.9%	<0.001
Quartile 4 – $1766.22 +	149	61.7%	238	21.4%	<0.001
by Year
1999*	0	0.0%	196	22.4%	<0.001
2000	309	53.1%	602	17.9%	<0.001
2001	289	63.0%	152	13.2%	<0.001
by Region
East	52	53.8%	149	20.1%	<0.001
South	269	60.2%	151	17.2%	<0.001
Midwest	232	57.3%	545	19.4%	<0.001
West	45	51.1%	105	9.5%	<0.001
by Age Group
< 18 Years	1	100.0%	39	33.3%	<0.001
18 – 34 Years	42	50.0%	83	14.5%	<0.001
35 – 44 Years	119	66.4%	221	16.7%	<0.001
45 – 54 Years	214	60.3%	353	17.3%	<0.001
55 – 64 Years	194	54.1%	238	18.9%	<0.001
65 + Years	28	39.3%	16	25.0%	<0.001

*Infliximab dosing for RA was not detectable via HCPCS code until June of 2000